

Geriatric Syndrome

Urinary Incontinence



Learning Objectives

Urinary Incontinence

At the conclusion of the module addressing incontinence in older adults, the learner should:

KNOW

- The presentation and symptoms of the most common types of urinary incontinence
- Behavioral and medication treatment strategies for urinary incontinence

DO

- Identify and use screening and assessment tools to aid in the recognition and management of urinary incontinence
- Recognize risk factors leading to urinary incontinence
- Optimize a treatment plan for an individual with urinary incontinence



Case

Mrs. Naehr

- Anh Naehr, is an 82-year-old widow residing in an independent living retirement community. Her daughter, the oldest of her three children, is involved with her care and checks in on her mom every day.
- Mrs. Naehr and her daughter approach the counter today to speak with their pharmacist. The daughter has the OTC product, **Oxytrol for Women®** (oxybutynin) and a package of high absorbency sanitary napkins in her hands. She reports that her mom has started having “urine accidents” daily (when she sneezes and when she cannot make it to the bathroom following the sudden urge to urinate). She asks if the medication and the sanitary napkins are the best solutions to her mom’s problem.
- Mrs. Naehr’s medical history includes HTN, osteopenia, allergic rhinitis and cognitive impairment (likely due to Alzheimer Disease); all conditions are stable on the following medications:
 - Lisinopril (Prinivil) 20 mg daily, CaCO₃/Vitamin D3 twice daily, Cetirizine (Zyrtec) 10 mg daily, Donepezil (Aricept) 5 mg daily, acetaminophen 325 mg as needed for minor pains.
- The pharmacist does not have access to any assessments or laboratory data.
- As Mrs. Naehr’s daughter finishes her question, the pharmacist is called away to the phone and in the effort to not delay the encounter, the pharmacy clerk checks out Mrs. Naehr and her daughter and they leave the pharmacy with the medication and the sanitary napkins.






Definitions

! Geriatric Syndrome

- A multifactorial condition prevalent in older adults that develops when an individual experiences accumulated impairments in multiple systems that compromise their compensatory abilities.



Definitions



Screening

- Screening tools are tests or measures to evaluate for diseases and health conditions before symptoms appear.
- Screenings allow for earlier management and referral to appropriate providers.
- An age-friendly provider conducts screenings for conditions that are prevalent in older adults.



Definitions

Assessment

- Assessment tools are tests and measures used to evaluate the patient's presenting problem, confirm a diagnosis, determine its severity, and aid in identifying specific treatment options.
- An age-friendly provider uses appropriate assessments, makes referrals, and communicates with the patient's care providers.



Definitions

Treatment

- An age-friendly care provider considers the 4Ms when making treatment recommendations so that **what matters** to the patient is always part of the plan of care.
- An age-friendly provider communicates with the patient, family, and interdisciplinary team.





Definitions

★ Incontinence

- Inability to control the flow of urine from the bladder (urinary incontinence) or the escape of stool from the rectum (fecal incontinence).

★ Urinary Incontinence


- Inability to control the flow of urine. Types of urinary incontinence include stress, urge, overflow, and functional incontinence.

★ Fecal Incontinence

- Also known as bowel incontinence; the inability to control bowel movements, causing stool (feces) to leak unexpectedly from the rectum. It can range from an occasional leakage of stool while passing gas to a complete loss of bowel control.



Know and Use the
Shared Language...
we are all connected



Statistics

UI Statistics^{1,2}

- UI crosses all racial, ethnic, and geographic boundaries and affects about 13 million American older adults
 - UI may be underreported in nonwhite populations
- UI affects all age groups with peak incidence in women (about 50%) around the age of menopause and a steadily increasing prevalence after age 65. Yearly screening is recommended for women
- UI is reported in about 45% of older adult men
- UI is associated with reduced levels of social and personal activities, increased psychological stress, and overall decreased quality of life




Statistics

UI Statistics^{1,2}

- Many variables contribute to the prevalence depending on type of UI and setting :
 - 10% - 30% of community dwelling older adults;
 - 30% - 35% of hospitalized older adults;
 - 50% - 85% of residents of nursing homes.
- The direct cost of UI include the costs for diagnoses, treatment, and routine care.
 - In 2020, the direct cost of treating overactive bladder (OAB) UI was estimated at over \$82.6 billion.
- Due to caregiver burnout, UI is often a contributor to the decision to place an older adult in a skilled nursing facility for care.




Risk Factors



Symptoms

Symptoms Associated with UI^{3,4}



Involuntary Urine Loss



Types

Types of UI ^{3,4}

Stress (SUI)

Urine loss when sneeze or cough:
Low sphincter tone

Urge (UUI or OAB)

Sudden urge to urinate:
Too much activity in bladder muscle
(**O**veractive **A**ctive **B**ladder)

Overflow

Urine leaks from a bladder that is always full:
Cannot hold any more

Functional

Normal bladder control but barriers to toileting are present:
Cannot access the toilet

Mixed

Combination of any two or more





Screening



Assessment



Treatment





UI Screening Questions³

The age-friendly provider should focus on **urgency** (impulse), **nocturia** (>3 times per night), and **frequency** (>8 times per day) in asking these questions:

- Do you ever leak urine when you have a strong urge on the way to the bathroom? How often?
- How frequently do you empty your bladder during the day?
- How many times do you get up to urinate after going to sleep? Is it the urge to urinate that wakes you?
- How many pads a day do you wear for protection?
- Does this problem inhibit any activity or prevent you from doing things you like to do?





UI Assessment Questions^{3,4}

The more detailed assessment of UI includes information from the patient's history:

- What is the history of onset, nature, duration, severity, and bother of urinary tract symptoms?
- What is the medical and surgical history? If applicable, what is the obstetric and gynecologic history?
- What is the thorough medication history, including prescription medications, nonprescription medications, and natural/ herbal products?
- What is the review of systems, including genitourinary and neurologic findings?
- What does the objective data reveal?

Urinalysis, Chemistries, Urodynamic testing, Cystoscopy, Imaging





Conditions Associated with UI^{3,4}

- D-I-A-P-P-E-R-S*

Delirium

Infection

Atrophic
Urethritis/Vaginitis

Pharmacology

Psychological
Disorders

Endocrine
Disorders or
Excessive Urine
Output

Restricted Mobility

Stool Impaction

*Especially useful in acute onset UI





Medications Contributing to UI

Medications that cause an Increase in Urine Volume or Frequency

- Diuretics
- Caffeine
- Alcohol
- Antihypertensives

Medications with Anticholinergic Activity

- Antihistamines
- Medications with the side effect of anticholinergic activity

Medications with Sedating Activity:

- Sedative hypnotics
- Narcotic analgesics
- Medications with the side effect of sedation





Medications Contributing to UI:1

Medication Class	Example Medications	Proposed Mechanism	Signs/Symptoms of UI
Anticholinergics	Amitriptyline (Elavil), Diphenhydramine (Benadryl) Risperidone (Risperdal)	<ul style="list-style-type: none"> Decreased detrusor muscle contraction 	<ul style="list-style-type: none"> Hesitancy Straining to Void Overflow UI
Diuretics	Furosemide (Lasix) Hydrochlorothiazide (Esidrix)	<ul style="list-style-type: none"> Increased urine volume Altered mental status 	<ul style="list-style-type: none"> Polyuria Frequency Urgency Leakage
Sedative Hypnotics	Diazepam (Valium) Lorazepam (Ativan) Triazolam (Halcion)	<ul style="list-style-type: none"> Sedation Obtundation Altered mental status 	<ul style="list-style-type: none"> Nocturia Functional UI
Narcotic Analgesics	Codeine (alone or in combination) Hydrocodone (ZohydroER) Fentanyl (Actiq) Morphine (MS Contin)	<ul style="list-style-type: none"> Sedation Altered mental status Causes constipation 	<ul style="list-style-type: none"> Hesitancy Straining to Void Overflow UI Functional UI





Medications Contributing to UI:2

Medication Class	Example Medications	Proposed Mechanism	Signs/Symptoms of UI
Alpha-adrenergic antagonists <small>Same drug class is used to manage Overflow UI</small>	Prazosin (Minipress) Terazosin (generic) Doxazosin (Cardura)	<ul style="list-style-type: none"> Decreased urethral resistance 	<ul style="list-style-type: none"> Frequency Urgency Leakage
Alpha-adrenergic agonists <small>Same drug class is used to manage Stress UI</small>	Pseudoephedrine (Sudafed)	<ul style="list-style-type: none"> Increased urethral resistance 	<ul style="list-style-type: none"> Hesitancy Post-void Dribbling Urinary Retention Overflow UI
Calcium channel antagonists	Nifedipine (Adalat CC, Procardia XL) Verapamil (Calan SR)	<ul style="list-style-type: none"> Decreased detrusor muscle contraction Causes constipation 	<ul style="list-style-type: none"> Hesitancy Post-void Dribbling Straining to Void Urinary Retention Overflow UI
Alcohol	Ethyl alcohol	<ul style="list-style-type: none"> Increased urine volume Sedation Altered mental status 	<ul style="list-style-type: none"> Frequency Urgency Nocturia Functional UI






Medications Contributing to UI:3

Medication Class	Example Medications	Proposed Mechanism	Signs/Symptoms of UI
Muscle relaxants	Baclofen (generic) Orphenadrine (generic) Tizanidine (Zanaflex)	<ul style="list-style-type: none"> Decreased urethral resistance Causes constipation 	<ul style="list-style-type: none"> Frequency Urgency Polyuria
Nonsteroidal anti-inflammatory agents (NSAIDs)	Ibuprofen (Motrin) Naproxen (Naprosyn)	<ul style="list-style-type: none"> Prostaglandin inhibition Decreased detrusor muscle contraction 	<ul style="list-style-type: none"> Hesitancy Post-void Dribbling Straining to Void Urinary Retention Overflow UI
Angiotensin-converting enzyme inhibitors (ACEIs)	Benazepril (Lotensin) Enalapril (Vasotec) Lisinopril (Prinivil, Zestril)	<ul style="list-style-type: none"> Cause coughing that can contribute to Stress UI 	<ul style="list-style-type: none"> Frequency Urgency Leakage
Cholinesterase inhibitors	Donepezil (Aricept) Galantamine (Razadyne) Rivastigmine (Exelon)	<ul style="list-style-type: none"> Increased detrusor muscle contraction 	<ul style="list-style-type: none"> Frequency Urgency Leakage Nocturia
Lithium	Lithium (Lithobid)	<ul style="list-style-type: none"> Causes polyuria 	<ul style="list-style-type: none"> Frequency Urgency Leakage Nocturia





Behavioral/Lifestyle Changes for Treatment of UI*



***Implement based on patient's cognitive abilities and caregiver involvement**





Treatment Options for Urinary Incontinence

Urinary Incontinence Products:

Referral to and counseling by a health care team member for an appropriate incontinence product.

Pelvic Floor Strengthening:

Referral to and evaluation by a physical therapist for prescription for pelvic floor muscle exercise or other exercise. Innovative medical devices are becoming available

Medication Therapy:

Referral to and counseling by a prescriber or pharmacist to identify and discontinue inappropriate medications or initiate new medications depending on the type of UI.





Comparison of Products to Manage UI

Light to Moderate Urine Loss		
Product	Description	Comments
Pantiliners (Women) or Shields (Men)	Very thin, Discreet, Contoured to fit either female or male anatomy	Available in different absorbency levels
Perineal Pads	Designed with super absorbent materials	Available in several absorbency levels
Guards (Men)	Contoured designed to fit the male anatomy	Designed for moderate urine loss
Moderate to Heavy Urine Loss		
Product	Description	Comments
Protective Underwear/Adjustable Underwear	Designed for female or male anatomy	Available in several absorbency levels and washable or disposable options
Fitted Briefs	Designed for urine and/or bowel loss	Available in several absorbency levels
Reusable Pants (to hold liners)	Designed to keep pads in place	Unisex; Designed for multiple washes
Disposable Liners	Designed for use with reusable pants	Available in several lengths and absorbency levels
Pads or Bed Protectors	Designed for placement under the perineal area to provide a barrier between the patient and the bed	Change often to prevent infection and/or skin breakdown
External Catheters	Most effective in managing overflow incontinence	Proper training and attention to hygiene is important to prevent infection
Prevent Urine Loss		
Product	Description	Comments
Bladder Supports (Women)	Designed to stop leaks before they happen	Available as a tampon-like product in three sizes Pessary is an alternative

**Implement based on patient's cognitive abilities and caregiver involvement;
Attention to perineal hygiene is important when using any of these products**





Medications Used to Manage UI

Urge Incontinence or OAB

*Oxybutynin (Ditropan)

*Tolterodine (Detrol)

*Trospium (Sanctura)

*Solifenacin (Vesicare)

*Darifenacin (Enablex)

*Fesoterodine (Toviaz)

^Mirabegron (Myrbetriq)

+Soy germ & Pumpkin seed extract

#onabotulinumtoxinA (Botox)

*Consider anticholinergic side effect profile prior to prescribing;

^Alternative to anticholinergics;

+Inadequately studied but safe

#Use in anticholinergic failure or intolerance

Stress Incontinence

Estrogens – Local or [§]Systemic

[§]Ephedrine

Duloxetine (Cymbalta)

Venlafaxine (Effexor XR)

[§]Consider side effect profile prior to prescribing

Overflow Incontinence

Prazosin (Minipress)

Terazosin (generic)

Doxazosin (Cardura)

+Saw palmetto

+Inadequately studied but safe





Referral to Clinical and Community Support

- Information for managing UI is available at the website of the National Association on Continence at <https://nafc.org>
- Available information and resources includes:
 - Connecting with incontinence communities and support groups,
 - Locating centers of excellence,
 - Printable materials for managing continence,
 - Sources of continence supplies.
- The local community pharmacist, health care provider, or hospital discharge planner are valuable resources who can provide information and referrals to help manage incontinence.



Remember Mrs. Naehr?



Un-Age-Friendly Care (4Ms)


Suggest limiting activities outside of the residence and with unfamiliar access to bathrooms.

Consider admitting to a skilled nursing facility for care (specific for UI care).

Do not consider or address barriers to toileting.

Wear clothing that is difficult to remove prior to toileting.

Do not consider pelvic floor exercises.



Avoid review of medications that could contribute to UI.

Prescribe anticholinergic medication for UUI in a patient with cognitive dysfunction.

Prescribe medications that manage UI but contribute to cognitive dysfunction.

Do not consider cognitive status in selecting incontinence products.

Do not consider anxiety or depression related to UI.



Age-Friendly Care (4Ms)

LISTEN & VALIDATE

Consider patient autonomy and level of desired independence.

Consider caregiver availability and input.

Recommend appropriate UI products and assure correct use.

Recommend/assure appropriate perineal skin care.

SCREEN & REFER

Assess toileting access and prescribe DME (portable/raised toilets) as appropriate.

Assure clothing allows for easy access to toileting.

Prescribe pelvic floor exercises for management of SUI.

WHAT MATTERS



MEDICATION



Mrs. Naehr

MOBILITY



MIND



SCREEN & REFER

Prescribe mirabegron for management of UUI.

Recommend appropriate UI products.

Consider topical estrogen therapy.

Avoid medications that contribute to UI.

SCREEN & REFER

Address cognitive function.

Screen for depression and anxiety.

Avoid medications that negatively affect cognitive function.



Clinical Pearls

Evaluating Urinary Incontinence

- When evaluating UI, always rule out any medication causes.
- Determining a specific type of UI will allow for more appropriate management.

Managing Urinary Incontinence

- First line-treatment for most types of UI involves nonpharmacologic options which include pelvic floor exercises and UI products as appropriate. In most cases, these options should be continued when medication therapy is initiated.
- Consideration of the older adult's cognitive status and availability of caregiver input is important.



About Engage

An interdisciplinary team of clinician-educators

Susan W. Miller, BS Pharm, PharmD

Leslie F. Taylor, PT, PhD, MS

David W.M. Taylor, PT, DPT

Jennifer de la Cruz, MMSc, PA-C



engage

Together for Tomorrow



georgiagear

ENGAGING FOR BETTER HEALTH

Engage is part of Georgia Gear, a multi-institute partnership whose goal is to improve clinical care and quality of life for older adults and their families.

Contact us at engage@mercer.edu

Work of the Georgia GWEP is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of Award Number U1QHP33070 totaling \$3.75M with 0% percentage financed with nongovernmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

Presentation design by Reckon Branding.



References

1. Gorina Y, Schappert S, Bercovitz A, Elgaddal N, Kramarow E. Prevalence of incontinence among older Americans. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Vital Health Stat 3(36). 2014.
2. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen C-I, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130-140.
3. <https://www.nia.nih.gov/health/urinary-incontinence-older-adults>; accessed June 2, 2022.
4. Resnick NM, Yalla SV. Management of urinary incontinence in the elderly. N Engl J Med. 1985;313(13):800-805.
5. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001;76:358-363.
6. Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010;183:1892-1898.
7. Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120:562-575.
8. [Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline from the American College of Physicians \(ACP\). 2014](#)



Continue to **ENGAGE...**

with your patients, their families,
your colleagues, and your
communities.

Together for Tomorrow



engage
Together for Tomorrow

